Eden Research Share Price (EDEN)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Eden Research Plc	LSE:EDEN	London	Ordinary Share	GB0001646941	ORD 1P

	Price Change	% Change	Share Price	Shares Traded	Last Trade
	0.00	0.00%	10.40	5,201	08:00:00

Bid Price		Offer Price	High Price	Low Price	Open Price
10.00		10.80	10.40	10.40	10.40

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Pharmaceuticals & Biotechnology	2.77	-0.53	-0.16		22.0

Last Trade Time	Trade Type	Trade Size	Trade Price	Currency
09:37:41	O	106	10.12	GBX

Related Shares
Astrazeneca (AZN), Glaxosmithkline (GSK), Bermele (BERM), Valirx (VAL)

Eden Research (EDEN) Latest News

Eden Research News

Date	Time	Source	Headline
08/7/2019	07:00	UKREG	Eden Research plc Change of Adviser
28/6/2019	14:43	UKREG	Eden Research plc Replacement - Grant of Awards
28/6/2019	11:43	UKREG	Eden Research plc Grant of Awards under Long-Term Incentive Plan
28/6/2019	07:01	UKREG	Eden Research plc Director/PDMR Shareholding
12/6/2019	07:33	ALNCF	Alliance News Flash Headline
12/6/2019	07:00	UKREG	Eden Research plc Appointment of Commercial Director
15/5/2019	08:10	UKREG	Eden Research plc Result of AGM
14/5/2019	16:13	ALNC	Eden Research Says Poised To Benefit From More Pesticide Regulation
14/5/2019	07:00	UKREG	Eden Research plc AGM Statement
09/5/2019	13:21	ALNC	Eden Research's Local Partner Secures First Cedroz Sales In Italy

More Eden Research News

Eden Research Takeover Rumours

Eden Research (EDEN) Share Charts

1 Year Eden Research Chart

1 Month Eden Research Chart

Intraday Eden Research Chart

Eden Research (EDEN) Discussions and Chat

Eden Research Forums and Chat

Date	Time	Title	Posts
16/7/2019	11:14	Eden Research	6,590
12/7/2019	07:18	Eden Research; novel encapsulation and delivery technologies	543
07/3/2017	13:47	Eden Research- The Natural Solution	172
27/2/2016	11:20	Eden Research- The Natural Solution	3
18/5/2012	02:24	Eden Research	6

Add a New Thread

Eden Research (EDEN) Most Recent Trades

Trade Time	Trade Price	Trade Size	Trade Value	Trade Type
08:37:42	10.12	106	10.73	O
07:07:27	10.56	5,095	538.03	O

View all Eden Research trades in real-time

Eden Research (EDEN) Top Chat Posts

Date	Subject
16/7/2019 09:20	Eden Research Daily Update: Eden Research Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker EDEN. The last closing price for Eden Research was 10.40p. Eden Research Plc has a 4 week average price of 10.40p and a 12 week average price of 10.35p. The 1 year high share price is 13.75p while the 1 year low share price is currently 9.13p. There are currently 207,189,337 shares in issue and the average daily traded volume is 34,388 shares. The market capitalisation of Eden Research Plc is £21,547,691.05. Read Full Thread Reply
11/6/2019 00:33	investingisatrickygame: From Super's post, number 6400 hxxps://www.crophealthnorth.co.uk/wp-content/uploads/2019/03/EdwardsGwynn-CropTec-widescreen.pdf The global market for biopesticides in 2019 is $6 billion From Eden's 2018 AGM presentation "Globally, Eden is one of a few biocontrol companies with proven products and regulatory authorisation" Eden's market Cap is circa £22 million So which of the other 'few' global players has all the value & the sales? And what are their market caps? And how do they differ from Eden? It appears increasingly strange to me that Eden makes such statements and yet the divide between the statement and Eden's value is like a chasm. These things need better consideration and deeper explanation if people are to buy the Eden share price. In theory, based on Eden's statement and the 2019 market value then Eden should be priced at £'s, not pence. 'Professional' investors in the City have investment rules, will look for the onset of deep profits, dividends & more. Eden has thus far been unable to penetrate this market and Powerscourt have been unsuccessful in inducing that investment into Eden. Private investors don't have those rules, they look to get in early and cheap and they look for high capital growth and which point the 'professionals' step in and invest and the Pi's retreat, happy with their ROI. Eden still needs to address the latter and convince them to buy, something they continually demonstrate a lack of will to do Read Full Thread Follow Reply
30/5/2019 09:42	investingisatrickygame: I know a number of people are really fed up with the ongoing lack of value being reflected in the share price. I certainly am. How long, even in a regulatory framework, can one continue with the mantra that these things take time, especially when we have two commercial products, delivered via Sustaine, with Sustaine (we assume, not unreasonably) having successful trials elsewhere with Agrochemical majors and full confirmations still to come alongside commercial arrangements. Mevalone is now a global product as a result of Sipcam's uptake right's. It is, we are told, being used now as a pre-harvest, 'protector'/'insurer' against the possible later onset of Botrytis and it has post harvest viability too. Exempt from MRL & Generally Regarded As Safe (GRAS), Mevalone is the Natural Solution. From a marketing perspective, Eden and Powerscourt have everything to hand here except organic status. This story can run well either with the support of the press or stand alone using video and distribution partners to place in the right channels for understanding and word-of-mouth. Many people should be talking about Eden to the positive and it should create its own direction of travel. This is before we even address Cedroz which has a bigger impact, plus the awaited new products in bigger markets. You can take a definition from wherever you want, I've taken the easiest to find. "The chief executive officer (CEO)[1] or just chief executive (CE), is the most senior corporate, executive, or administrative officer in charge of managing an organization – especially an independent legal entity such as a company or nonprofit institution. CEOs lead a range of organizations, including public and private corporations, non-profit organizations and even some government organizations (e.g., Crown corporations). The CEO of a corporation or company typically reports to the board of directors and is charged with maximizing the value of the entity,[1] which may include maximizing the share price, market share, revenues or another element. In the non-profit and government sector, CEOs typically aim at achieving outcomes related to the organization's mission, such as reducing poverty, increasing literacy, etc. In the early 21st century, top executives typically had technical degrees in science, engineering or law.[2]" From above "The CEO of a corporation or company typically reports to the board of directors and is charged with maximizing the value of the entity,[1] which may include maximizing the share price" I have no issue with Sean's online delivery, nor his connections, nor his IP knowledge and background. I have no basis to, I doubt anyone does. However, he is not maximising the share price. It cannot be argued one day Rodney, when so many days have passed with the result of the above products, relationships and technology. And we have a former high ranking employee of Bayer as our Chairman which doesn't on the face of it after 18 months in situ, appear to be delivering anything of value that we as shareholders can measure. That is fair observation. A CEO has to deliver share price value and that has to be on an ongoing basis, trending upwards and in line with business performance + forward prospects, traditionally measured on a three year timeline. Eden has nothing factored in for the latter and much of its business achievement thus far not factored in to today's share price. It is illogical and unrealistic to expect that one moment in time, yet to come, will catapult the share price north and vertical in an instant and correct all share price performance woes to-date. That if it ever happened, would lead to a mass sell out and a decline in the share price as quick as the incline that occurred. The CEO of Eden has to maximise the share price now and this is an ongoing role and responsibility. it isn't to be implemented when you wish to. It is an ongoing process. NDA's, partners et al do not have the power to supress another's share price and it is unthinkable to imagine this can be so. I know the BoD will read this and other posts and I know they will know who wrote this. I have no ill will towards the BoD, but our CEO whoever that may be an any point in time has to do their utmost to ensure that the share price of today and every day reflects the true value of the Company today. If they truly believe our share price and market cap is fair value right now, then do nothing at circa £23 million. If however this is not what they believe and know value to be, then they need to act to move the share price and show their audience true reasons why the share price should be much higher and therefore why people should invest in it today. This 'moan' by many is not going to go away until it is dealt with. Institutions are not and do not buy into Eden at this level. So they truly have no options but to stir up the market and in due course the hoped for institutions might come on board. Is our current CEO going to be the CEO to put value into the share price today based on current achievements or is another going to be brought into the business to deliver that value today, as well as the ongoing process of creating value for the future, the latter of which I am sure Sean is seeking to achieve. Read Full Thread Follow Reply
24/5/2019 15:05	investingisatrickygame: Brucie5, I think a market penetration of 3.5% is way under from my discussions with other shareholders. In a Bio market as you say that has healthy CAGR in its favour, from Eden's very low starting base, from the partners it has, I believe that number is well understated. Shore capital had 5% and look how dismal the share price number was on the back of that. Eden is a tech company and a bigger tech company in the waiting. Sipcam, Bayer et al trials when confirmed as successful should mean Eden is a Crop Protection tech company and should position Eden in a totally different way with significantly higher expectations and market excitement. Little apparent success in Consumer Health and Animal Health and these have been on Eden's Powerpoint presentations for years. they mean nothing at this stage and Eden give them no importance either. Eden needs a refocus/revamp in my opinion. All that gets talked about on here is trends and changing opinion (which is good but is not affecting your wealth to the positive). One could argue Eden is all industry focused and not investment focused. There is no balance and harmony in what they do. If we listen to Eden and we all do, there is no reason given by the Company to invest in today's share price. They give the impression that there is plenty of time to do so and no need to hurry. The share price reflects the same. The story is still not told, nor the opportunity, not the proximity of that investment opportunity. You, wan, Super, AttyG and others on here may understand it, but not enough do and still, therein lies the problem. If the options due in September 2019 pass, the BoD will simply write more, so their position is forever protected from an income and growth perspective. I fail to understand the lack of importance placed on the share price by the Company executives. Livingbridge, Finn and others, private investors cannot and will not I'm sure, accept the dormancy that the BoD allows to persist in the share price. Artemis appear to be selling and whatever their reasons, they're in part, selling. No PR firm, and Powerscourt for all of their global reach has done anything for Eden. Perhaps they might argue that they are constrained monthly fees and remit. If so, Eden is quite able to communicate independently of a PR firm. They are not needed at this stage of Eden's development and no one can say they have been used, successfully. A broker is a regulatory requirement, but one that supports, understands and generates investment in Eden would be welcome. For now and the trend over the last 3-5 years is clear, Eden needs to do the driving of the share price themselves and they need to do it better. Read Full Thread Follow Reply
15/5/2019 16:06	investingisatrickygame: Eden, the Snail in the Garden I see Michael Walters has it spot on this time. There is a great deal of frustration around the Eden share price! The problem is that Eden is not allowed to tell common garden investors what is in the shore cap report even though as owners of the company we have paid for it via fees to the brokers! Fairly basic Proactive chats are no substitutions for real projections (that we all can see. Absence of proper broker support available to the private investor! Can the board come up with a new ay of marketing the shares? I have been posting the same on here for years, much to the frustration of some here and on other BB's, but it really is obvious. Perhaps Eden will now listen to Michael Walters. Eden has no traction in the City in regards to buying a position in Eden. Powerscourt who are meant to further the same have made no visible gains. Thus, the Shore Cap report is useless as it falls on deaf ears and a blind audience. They are not looking to see. An independent report by the likes of Edison or whomever similar would have far greater applicable reach to an audience with ears and eyes that will listen, namely the private investor. Furthermore, they are always looking for capital growth and are only restrained by the £ in their pocket, but they will buy and will buy quickly if the story adds up. Shore Caps clients will of course not respond the same. What is the market cap (oh they're too small), they're on AIM (no good), we do invest in green stocks, but none so young as Eden. The reason are extensive and an investment is often a far more complicated decision. Not so with the private investor. Eden does need to find a new way of marketing the shares, but in the first place they need TO MARKET THE SHARES. Eden do not market their shares and their toe in the water with Proactive is merely a series of process updates, albeit well explained, but they never give an investor a reason to buy and consequently, they don't. Eden must surely have learned its lesson over the last 2-3 years in regards to gaining investment in its share price, whom to target, why and how. Everything they have done, which is limited, has failed to incentivise people to invest, but then they have not targeted people (private investors). Eden sits at a market cap of circa £22 million. The narrative and the price still don't align It costs $25-$30 million to deliver a biopesticde to market, so $50-$60 million in total, almost three times our current market cap. The Chairman in the 2018 Annual Report says "the new products in the Company's pipeline aim to address markets which are potentially even bigger that those already covered by its existing products" Also he states " there is potential for an even greater opportunity around the use of Eden's proprietary, natural micro-encapsulation technology which is being teste by a number of third parties including some of the major agchem companies" Where is any of this in a three year forecast from the Company? How is this potential communicated to an investment public outside of this written word in the Annual Report. More importantly, how many people received a hard copy of the Annual Report and how many read/downloaded the PDF. Eden only talks to a few existing investors who are listening. The rest are asleep and the rest of their target audience has no idea who Eden is or the breakthroughs they are making. I very much doubt those not invested in Eden are reading our RNS's, why would they?! So MW is right, find a way to market Eden's shares to an audience that is willing to invest, willing to listen, available to listen and who equally importantly, will be your bag carrier of opportunity to other investors. In my opinion, if we sit here waiting for Powerscourt or a broker to unlock the door then Eden's shares will likely be dormant for some while to come. Finally and for Powerscourt, the world now seems to really understand that Pesticides are bad for you. Eat fruit, veg and nuts everyone; oh dear, they've been treated with pesticides, so maybe 5-a day is not as good for you as we suggested. Eden has a major PR opportunity right in the eye of the storm when readers will listen, journalists will listen and knock on Eden's door, doors will open for Powerscourt as a result of the same, the public will go to Eden's website to find out more, hey they might even invest. Why is Eden not challenging this when their share price is so low, their company value is so undervalued and the newspaper public, I'm sure, would love to hear about them. And it has nothing to do with a small employee base! Eden, one of only a few biocontrol companies globally with proven products and regulatory approval and yet, the investment world knows nothing about it!!!!! Read Full Thread Follow Reply
14/4/2019 22:17	investingisatrickygame: Super, Go back and look at the Proactive presentation uploaded on the 12th February 2019 and compare this with the Shore Capital note. From the Proactive presentation:- hxxp://www.edenresearch.com/~/media/Files/E/Eden-Research/documents/reports-and-presentation/eden-presentation-feb-19-proactive.pdf "Globally, Eden is one of the few biocontrol companies with proven products and regulatory authorisation" What value is this if the associated global market opportunities rank so lowly on the Shore Capital note? "The biopesticide market is projected to reach $8.8 billion by 2022" Eden's forecast market share by Shore Capital doesn't appear to resonate with the first statement above made by Eden "Neonicotinoid insecticides were worth $3.1 billion globally but are now facing withdrawal in Europe and elsewhere. Conventional crop protection products formulated with Sustaine and Eden’s active ingredients can help address many of these issues" An Eden statement which is not reflected at all in the Shore Capital note. How is our House Broker understanding Eden's publicly declared statements and therefore representing Eden properly to their investment community? "Eden's proven addressable market is $1.2 billion, tomorrow this grows to more than $2 billion, not including Sustaine" Again, no reflection by Shore Capital of Eden's buoyant and clear statements on opportunity. For example, how does the expected 5% market share projected by Shore Capital align with the above statement? On the last slide, page 28, look at points 2 & 3 which are most imminent and present. Nowhere does the Shore Capital reflect the story that Eden is telling publicly and backing up the Company's own enthusiasm (and let's be honest, Eden is so understated, it's untrue. I find it very frustrating that we, Eden, appear to be at odds with our House Broker whose numbers seem to me to be totally unrepresentative of Eden's current position, likely position in the next 2-3 years (e.g. Cedroz as one example) and pipeline position thereafter. Conventional pesticides are toxic by association, we are told conventional pesticides in some cases are not been renewed by regulators for future sales, bio alternatives is a fast growing market and supported by regulators and undoubtedly the wishes of the public and Eden is one of a few global players. Sustaine is still under evaluation by Sipcam (when do we get updated), it is a game changer according to Xinova (hxxps://www.xinova.com/work/eden-research/), Bayer Crop Science evaluating the same and likely others as indicated and we get a £50 million valuation from Shore Capital, maybe up to £98 million. Eden needs to put this right, surely. It was stated in the original Proactive presentation that Eden would deliver new forecasts to the market, through who? I believe these forecast are due in the next 8 weeks or so from memory. You cannot expect shareholders to keep getting slapped in the face, sitting in a static share price and expect them to stay invested in any "sustainable" way. It's not good for private investors and it's not good for Eden as a business. Read Full Thread Follow Reply
08/2/2019 13:30	investingisatrickygame: I didn't attend the presentation last evening, but what I take from it is as follows:- Source: [...] 1)It is the best, most specific, most relevant presentation that I have seen Eden deliver 2)Slide 3 "globally, Eden is one of the few biocontrol companies with a proven business". Based on this alone and referencing back to the Chairman's comments at the 2018 AGM, then it is nailed on that Eden is high and maybe even imminent in terms of actioning anything on such companies watchlist. So specifically, taking a stake, taking out a vertical, taking out Eden altogether 3)Slide 8, it would have been good to see more detail on Consumer Products as this part of the slide has been produced many times with little or no visible progress, head lice aside 4)Slide 11, finally qualified the annual value (2022 anticipated) of the biopesticide market & will be attacking the $3.1 billion neonicotinoid market through Sustaine encapsulation and co-encapsulation 5) Slides 9 & 12 somewhat qualify their intent to deliver in the 'slug' market 6) Slide 19 "Unique technology". How will anyone value that? Very interesting if they can clearly show a path to Sustaine helping them in their goal of being the "leader in sustainable bioactive products". Given the global statement in point 2 above, how far away is Eden from that now? With their distribution partners, what timeframe is likely to achieve that? Does this therefore increase focus on Eden now from industry players and does that heighten the potential for a hostile, or otherwise, bid? 7)Slide 20, Eden has qualified the value of their proven addressable biopesticide market; $1.2 billion, 14% of the global market projected value 8) Slide 21, Eden finally qualifies themselves that the entry to market is both time consuming and very expensive (previously not stated by Eden, but by chemical companies such as Syngenta). With biopesticides development costing 10% of that of traditional chemicals, with Eden established and again, point 2 above, that to me does again, place Eden front and central as a potential takeover/stake building target 9)Slide 26 UPDATED MARKET FORECASTS to be published during H1 2019. When were they ever publicly available? This sounds like a major step to me in terms of visibility to value. Via Eden, Edison or ANO? 10) Slide 29 Bayer Animal Health commercial launches. When? We've heard this so many times so a bit more underpinning and conviction to reassure everyone that it will finally happen would be worthwhile, assuming that wasn't given in speech last night. Best in print though so everyone can see when this presentation gets shared with others. Also "Accelerate commercialisation of Sustaine for conventional actives. So Sustaine encapsulation of others commercial chemical products. We could do with a more in-depth update on this in regards to Eden's evaluation agreement on the same with Sipcam It is the best and most convincing Eden presentation I have seen, underpinned by numbers, targets and soon to be, forecasts. As ChrisChas said, Eden needs to build upon this, re-emphasise this, broaden this and message to as wide a relevant audience as possible. Use film to cover this as it is more digestible and when delivered well, making Eden more investible. How much is an industrial tech company that has unique technology and is globally, one of the few bioactive companies with a proven business, worth? 12 years and $300 million cost is too long to wait as the train has left the station. Regulatory pressures going against traditional chemicals combined with the two points above makes Eden a no-brainer. So the stand out point in the presentation that makes no sense to private investors, hopefully makes no sense to institutional investors and I'm sure looks crazy to industry players is slide 3....Eden Market Cap £20 million Eden is so undervalued for investors and potential suitors alike that if Eden's share price was a £1 today, it wouldn't look stupid!!!!!!!!!!! Read Full Thread Follow Reply
02/2/2019 12:31	investingisatrickygame: Upcoming Week I think it is a big week in store for Eden. A non-performing share price for the last two years, it has sat in a very narrow and arguably low range. Shareholders have had no returns and given this is their intended outcome, I'm sure many will seek inspiration from this coming Thursday's inaugural investor audience presentation. I ask myself why are they doing this now? If it is to tell the story as is to a live audience then I personally would be very disappointed. I am hoping for, almost expecting positive RNS's this week. When Eden does announce via RNS the Bayer, TT, Sustaine announcements they (failing another strategic investment/partnership) will have delivered their last major RNS's for a while, at least to my mind. Therefore, when these announcements do come, they need some fanfare; what do they really mean for the Company; how will this leverage other aligned developments; what is the value of these deals; where does this place Eden? It's a terrific opportunity to really explain the value of Eden to everyone and this will need to be done for the share price to positively transform. We will of course have updates on Mevalone US and Cedroz companies coming on stream. These are all the value makers that sit before Eden and their shareholders right now. So I keep asking myself, what is the value of all of the above? This is what I want Eden to tell me, you and anyone and everyone who is willing to listen. With all of this in place and if not translated into the share price, why would Eden not be a bid target? Their share price in this scenario would be one of continuous underperformance and therefore would be available cheaply to an interested party with significant and imminent oncoming income streams. So potentially, a big week for Eden and to have investors understand all of this and to get the share price climbing. If not, then as an investment Eden to me would seem to be in limbo. Read Full Thread Follow Reply
24/1/2019 11:34	investingisatrickygame: GM Wan You make some interesting points "Are you saying you want a PR firm to put another spin on the potential/jam tomorrow stuff?" AND "Not all investors want the level of risk that a very small company like Eden currently presents, but when that changes or indeed starts to change, we should see a notable change" JAM TOMORROW I for one do not want any 'spin'. Equally, I am not interested today in Eden spouting their long list of patents which for most invested today, given lab and field trial times and regulatory approval leading to being on sale will have no material effect on their share price returns. Some of that may be 5 years away and many here will not be invested in Eden for the next 5 years! So, what is Eden all about and what is happening yesterday and today that will give me an investment return tomorrow, next week, next month and this year. You see, I'm tired having been in this for many years already and I am fed up of hearing about jam tomorrow. That story has been told one too many times!!!! LEVEL OF RISK I totally get that some will not want the level of risk that is associated with a company such as Eden and as such, they will not want to listen and they will not want to invest. However, what is the level of risk in investing in Eden today at 11-12p? Perhaps management should explain why Eden is fully de-risked at this price range so as to have potential investors understand Eden and the possible shareholder returns! This is a major part of delivering an investor communications programme to the same audience and this IS NOR PR, spin or any other like output. IS EDEN DE-RISKED AT 11-12P? 1) What is the value of Eden's IP? I am not talking about in Eden's balance sheet, I am talking about to other players on the agro-chemicals/biologicals markets. Here is an example of a products life journey to market and one which I am sure both you and Eden are familiar with hxxps://www.syngenta.com/how-we-do-it/research-and-development/how-we-make-new-products. The value line from 11p to somewhere along this path is in part, what needs to be conveyed to investors 2) What is the value of the Mevalone distribution rights & associated projected sales over the next 3 years? 3) What is the value of Cedroz distribution rights and associated projected sales over the next three years? 4) What is the value of TT headlice distribution rights and associated value of the next three years? A) When Bayer is shortly confirmed, what is the value of the Bayer distribution rights and associated value over the next three years? B) When Sipcam announces via Eden its findings on Sustaine encapsulation of Sipcam's current commercialised products and co-encapsulation opportunities with Eden's active ingredients, what will be the value of those tech rights over the next three years? If I was building the investment case in Eden via an Investor Communications programme, I would start at the very beginning introducing Eden, its management, its product and tech and come right through to the present on points 1-4 so that there was no spin, no PR, just a good solid understanding of the Company, what is does, Managements suitability for purpose and the audience would readily understand Eden's current income and value, three year projected forward income and value and would make their own decisions about 11p. I guarantee you, it would not stay at 11p for very long once all of that was delivered. I would also underpin the same programme of delivery with a research paper from Edison Research because they, better than anyone else, can deliver the same, reach out around the world and MOST IMPORTANTLY, ensure that Eden's current target audience can see the same and understand it, namely, private investors. Shore Capital et al are not allowed to deliver such papers to you and I to absorb and the audience they go to are not currently interested in Eden. When they are, fair enough. Walbrook PR, Powerscourt PR and all the others WILL NOT deliver this programme because they do not have the inclination to do so, the time, they would charge Eden too much, yet still (in my experience and opinion) not understand it. So in summary, I agree with you. Eden does not need PR, but at 11p it is de-risked to a share price level much higher than today. If the share price gets beyond itself, then again an investment would be a risk. However, in my opinion, 11p is so far away from risk, that it really is time management, if they believe the same, did the right thing and put the share price on a proper footing. If they feel they can't do it themselves (and their PR firms definitely can't), then find someone who can ( and I am not talking about me before anyone offers that commentary up)! Read Full Thread Follow Reply
02/1/2019 15:13	jaknife: Are we forecasting for the EDEN share price? Put me down for 2p by Xmas please. JakNife Read Full Thread Follow Reply
19/11/2018 13:47	investingisatrickygame: Super, Post 4904 is a brilliant find. I don't know where you find this stuff, but well done. Undeniably Eden, but like revenue stream many years in the future BACK TO THE PRESENT - RNS's DUE How on earth is Eden going to release up to 19 due RNS's by the 31st December 2018 and give them all the due credit, time, explanation, education and reach that they deserve, both within and beyond the RNS announcements themselves? How are they all going to make their relative impact and what will Eden & Powerscourt do to ensure this becomes a reality. There are circa 24+ working days left and no doubt the City will knock off early, in reality meaning less meaningful days as far as a Plc is concerned, mistakenly so in my opinion in AIM Stocks such as Eden which a primarily driven by you and me. Releasing such a slurry of news pre-Christmas also opens Eden up to a peak and trough with some taking rare profits in time for Christmas, should the share price spike in Eden. Eden appears to be leaving these all to the last minute which if so, is not good management of the same, if indeed this is taking place. With Eden telling us that there is such a small management team to address these news issues and investor communications, can they really afford not to pay due time and attention to these key RNS's that have been so long in the waiting? Eden can't afford to be a yo-yo share when news comes out. No one wants great prospects and then total insecurity in the share price when it should trade with less volatility. We're back to, in my opinion, that Eden must have a plan and they must execute it well. RNS's are not here to be thrown away. 14 have been released this calendar year and the share price has done nothing. There really is no more time to be bewildered by the share price and the lack of interest and corporate (Eden) value in the Mcap. It is time to take the share price seriously and deliver its associated value. To not do so is negligent in my opinion. Plc's reflect their corporate value within their share price. That is a fundamental reason for being listed; to create and deliver value. If Eden is waiting for parties to commit/sign on the dotted line or similar and know it is coming, then they have the knowledge and should create the time to deliver news more fully. RNS's and associated newsflow in the past has not been complementary to events. Eden has learned this and feedback from shareholders has said the same. How can Eden not deliver from all of the above knowledge and experiences, right this time, first time on this mass of key corporate news! Read Full Thread Follow Reply

Eden Research share price data is direct from the London Stock Exchange

Your Recent History

LSE

EDEN

Eden Resea..

Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US Finance Manila

P: V: D:20190716 12:21:34